Chris is an expert in technology strategy and commercialization who has worked in China and other countries in Asia for over 22 years. As well as being a co-founder and Director of Cyrcadia Asia, he is a partner in Rouse, an intellectual property consulting firm, where he has advised technology companies on their market entry strategies in China in the fields of consumer goods, consumer electronics, cleantech, industrial equipment, automotive and healthcare. He is also an Advisor to Southern Capital Partners, a boutique investment firm based in Shanghai, and several of its portfolio companies. Chris has an MA in Chinese from Oxford University, an LLM in Intellectual Property from the University of Edinburgh and an MBA from the Kellogg / HKUST joint program.

Chris joined CEO Rob Royea in launching Cyrcadia Asia in Hong Kong. Cyrcadia's award-winning technology is a wearable device which uses body sensors and AI to detect breast cancer. The device consists of patches which are worn under a bra for two hours a month. Sensors on the device send data via the users' smartphone app to our cloud-based predictive AI system to detect metabolic change consistent with tumor formation, with a proven accuracy in trials of 83%, as verified against pathology. A report is sent back to the user after two hours, with an alert to her physician if scan is positive. The technology represents a radical improvement against traditional screening methods such as mammography and will be a game-changer in early detection and saving lives, particularly in Asia where screening rates are low and mortality is high. Cyrcadia's technology has already gained a US FDA Class 2 clearance and the final commercial product will be launching in Hong Kong and other ASEAN markets in Q2 2018 on closing its Series A raise.

Chevy Beh is a contributor to Forbes.com. He graduated from the University of Virginia with a double major in Economics and East Asian Studies. Was awarded the “Most Promising Entrepreneurship Award” at the 2012 Asia Pacific Entrepreneurship Awards (APEA), Top Nominee for the “Ernst & Young’s Entrepreneur of the Year” for two consecutive years 2013 & 2014, and “Great Entrepreneur” Brand Icon Leadership Award 2015 by Brand Laureate. In 2016, he is nominated for MIT Technology Review, Innovators Under 35 Asia. He’s very passionate about Polo and was the first in Asia ever awarded the National Inter-Collegiate American All Star in 2007. Beh is a frequent speaker at healthcare, technology and leadership conferences, domestic as well as International.

Michael has over thirty years of experience in technology management and financing in Silicon Valley, Wall Street, China and Hong Kong.

​

Michael is also a Senior Consultant for SRI International (the Stanford Research Institute) and their chief representative in Hong Kong. SRI is a world-renowned Silicon Valley based research lab, which has created innovations such as the first computer mouse and Siri.

​

Michael advises Hong Kong and China-based firms on capital formation strategies. Previously, Michael was a founding partner and Managing Director of a China focused Private Equity fund managing over US$260 million in assets.

​

Prior to moving to Hong Kong, Michael was a Managing Director of a New York based FINRA licensed broker dealer providing financial advisory and capital markets services to small cap companies focused on technology, energy and alternative fuels.

​

Michael has held senior positions at Intel Corporation, including Chief-of-Staff to the CEO and Founder Dr. Andrew S. Grove, and General Manager of Intel China. He has set up and managed Private Equity funds in China and has been a strategic advisor to numerous start-ups in China and Hong Kong.

​

Michael holds a B.Sc. and M.Sc. in Electronic and Electrical Engineering from the University of Manchester.

Al Chalabi is an entrepreneur and business advisor with an impressive track record in a range of industries.

He grew up in the UK and studied Aeronautical Engineering at the University of Southampton. Al started his professional career in Canada, working as an engineer in process automation systems. After obtaining his MBA, he worked as a management consultant, specialising in technology, strategy and operations, and has been based out of Hong Kong ever since.

Since 2008, Al has been running CASP-R, a firm he founded to provide independent research and advisory services to investors and corporations, with a focus on real estate and technology. He is active in various Hong Kong-based angel investor groups that provide seed funding to Asian-based tech and healthcare companies.

Juvenescence is Al’s sixth book. He has been writing books with his co-author Jim Mellon since they first joined forces to write Wake Up! Survive and Prosper in the Coming Economic Turmoil, published at the end of 2005.

Professor Allen Chan is renowned scientist and entrepreneur in biotechnology industry. He has pioneered the development of noninvasive approaches for prenatal testing and cancer detection based on the analysis circulating DNA in blood plasma, and is an inventor of over 40 patent families. In 2017, over 4 million noninvasive prenatal tests for Down syndrome were performed using the technology invented by Allen. Together with Professors Dennis Lo and Rossa Chiu, Allen founded two biotechnology companies, Xcelom and Cirina. The two companies focus on Noninvasive prenatal testing and noninvasive diagnosis of cancers through plasma nucleic acids analysis, respectively. He served as founding director of the two companies. He also served as the chairman of the board of directors of Cirina (Hong Kong), a subsidiary of Cirina, to oversee the launching of the cancer screening service in Hong Kong. In 2017, Cirina has merged with Grail, a US-based startup company established by Illumina, the largest DNA sequencing system manufacturer. The merged entity is one of the most valuable companies in the field of liquid biopsy.

​

Regarding cancer screening technologies, Allen led the first large-scale prospective study of using “liquid biopsy” to screen for early asymptomatic cancer. Through the screening of over 20,000 asymptomatic participants, he demonstrated that the detection of cancer-derived plasma Epstein-Barr virus DNA could lead to the identification of nasopharyngeal carcinoma at significantly earlier stages compared with patients without undergoing screening. This work was selected as one of the ten notable article published in New England Journal of Medicine in 2017 because this study demonstrates that plasma DNA analysis is sensitive enough to detect very early cancer. This approach can potentially be applied for the screening of virtually all types of cancers through DNA sequencing.

Scarlett Chen heads up Strategic Investments for Prudential Corporation Asia. In her current role, she mainly focuses on investments in early to growth stage startups in the fintech, Insurtech and healthtech space. Before joining Prudential in 2016, she headed up FIG (Financial Institutions Group) for Anbang Capital and co-headed APAC Investments. Before this, Ms. Chen was an investment banker for more than a decade, having worked at Merrill Lynch and Barclays, mostly in the US, focused on capital markets and advisory transactions.

Focused on healthtech and blockchain, Bonnie leads 500 Startups' operations from HK. 500 Startups is one of the most active seed investors globally with over 1800+ portfolio companies including Prenetics, uBiome, MyHealthTeam and Siren Care.  Formerly head of strategic planning for the Zuellig Group, holding company of Zuellig Pharma and EBOS (NZE:EBO) for 7 years, Bonnie is passionate about finding disruptive technology companies that can change the traditional business models.  Prior to joining the healthcare industry, Bonnie is an enterprise software veteran having worked with IBM, AT&T, HP, Deloitte etc. She is a chartered CFA and holds a double major B.A. in Engineering & Economics from Dartmouth College.

Dr. NT Cheung is the Head of Information Technology & Health Informatics and Chief Medical Informatics Officer of the Hong Kong Hospital Authority (HKHA), and also the Consultant for eHealth for the Hong Kong Government. He has taken HKHA from a virtual “green
fields” site to today’s situation where clinical information systems have become ubiquitous and
indispensable in the care delivery process. His current work focuses on taking the Hospital Authority’s Clinical Management System (CMS) on a generational leap, working with clinicians and executives and embracing innovative IT and data driven approaches to enable new
and enhanced healthcare service delivery models. He also works with the Government and other stakeholders to develop the recently launched territory-wide Electronic Health Record Sharing System in Hong Kong.

NT is active in the informatics research and education communities, and is a frequent speaker at international conferences. He holds a medical degree from the University of Sydney and a Master’s degree in computing science from Imperial College, London.

Dr. Kenneth J. Chu Programs Director of Biorna Quantics. He is a naturopathic doctor in Hong Kong and board member of the Integrated Association of Naturopaths HK, IANHK. Ken uses an eclectic and holistic healing approach, using a mix of clinical nutrition and botanical medicine to address the root cause of a patient’s concern(s). He has sub-specialties are in sports medicine, pediatrics, and gastroenterology.

After his Bachelors degree from the University of Alberta, Ken graduated in 2006 from the Canadian College of Naturopathic Medicine (CCNM) in Toronto. Ken has further education
in advanced clinical nutrition, attending workshops and courses from around the world.
Furthermore, Ken has continued training from the sports medicine rotation at CCNM and
has treated many athletes, including some of Canada’s best Olympians and amateur MMA
athletes.

After moving to Hong Kong 7 years ago, Ken continues his work in naturopathic medicine.
His scope at Biorna Quantics involves seeing patients, R&D, and designing training modules
and seminars for practitioners and wellness clinics throughout Asia.

Dr Tak-Yi Chui is the undersecratary for Food and Health of the government of Hong Kong. He graduated from the Faculty of Medicine, University of Hong Kong, in 1981. He has served in the public health care system of Hong Kong for more than 30 years. His current duties are to assist and support the Secretary for Food and Health in the setting of policy objectives and priorities on agriculture, fisheries, food safety, veterinary public health, environmental hygiene, medical and health, and related implementation issues, handling Legislative Council business and strengthening the working relationship with Legislative Council, and engaging and liaising with all stakeholders to explain and solicit support for government policies and decisions.

Ildar Fazulyanov is a serial entrepreneur with over 20 years of experience in healthcare, fintech and venture capital. He founded Well, Inc. over two years ago with a mission to provide access to highest quality care to everyone. Ildar has managed all aspects of running a successful healthcare business, including accounting, business development, Medicare licensing, recruiting clinicians, sales, marketing and HIPPA compliance. Prior to WELL Ildar founded and completely bootstrapped Greener Equity, a successful fintech company, sold to Econ Partners. Ildar started his career at Bain & Company. He worked for DB Alex. Brown and was part of a launch of DB Advisors from an internal trading desk to multibillion dollar hedge fund. He also worked in Venture Capital at vSpring Capital ($450M AUM), now Signal Peak Ventures. Ildar graduated with MBA from Tuck School of Business at Dartmouth with Tuck Scholar Distinction and degree in Economics from BYU Magna Cum Laude.

Chris has over 18 years of corporate business experience in M&A, direct investing, and information technology for leading global consumer products companies. He is now a Managing Partner for Click Ventures Fund III.

Since 2004 he has been an active angel investor in the USA, China, and Hong Kong with interests primarily in advertising technology, clean energy, and education. In 2015 he wrote the Taiwan chapter for Angel Financing in Asia Pacific.

​

Chris is a founding member of Giinseng, an organisation for the promotion and advancement of impact investing in early stage businesses that create a social or environmental impact in greater China.

​

Chris serves on several boards including London Business School Alumni of HK and Columbia Alumni Association of HK. He holds an MBA from Columbia Business School and London Business School. He received a bachelor in physics with honours from Case Western Reserve University.

Darryl G. Glover, Pharm.D, MBA is a Principal and Chief Clinical Officer (CCO) of iSolve. As CCO, Darryl creates the connections between the advantages of Advanced Digital Ledger Technology™ and the needs of the Biopharma, Life Sciences, and Healthcare Industries. He has been a frontline provider, manager, and worked internationally as head of marketing, COO, and CEO for a biochromatography company. He has co-founded and served as COO for two tech startups focused on healthcare and general recruiting. Darryl has authored or co-authored 10 publications and published a children’s book. He has an MBA from the University of Chicago Booth School of Business, Pharm.D from the University of the Pacific, and a BA in Biology from the University of California at Berkeley.

Hanif is the founder and CEO of Sinophi Healthcare, a company which invests in and manages hospitals in China, focusing on public general hospitals and selected specialty hospitals. Sinophi works in partnership with hospitals in China’s rapidly growing urban areas to deliver improvements in the delivery of healthcare. Sinophi brings to hospitals in China international hospital expertise and technology, and builds partnerships with leading UK and international healthcare service and product partners.

Earlier in his career, Hanif qualified as a doctor and practiced in the UK.  He then spent eleven years in investment banking in corporate finance, derivatives and asset management with financial institutions including Prudential-Bache in London and New York, and Société Générale (SocGen) in Paris and Hong Kong.  Returning to healthcare in 2000, Hanif undertook (as COO for Hong Kong) the restructuring of then HK-listed ehealthcareasia.com which he turned from loss to profit in nine months. This included the development of an innovative, web-based, combined medical claims processing and clinic management software and its implementation to Hong Kong’s largest physician group of over 700 doctors.  Hanif graduated in medicine from Cambridge University and received his MBA from The Wharton School, USA.

Xin Yun is the Chief Executive Officer and co-founder of LeadinHealth. Influenced by
her time working as a Ward Pharmacist in hospitals and active involvement in the
Ministry of Health’s policy development and planning, Xin Yun realised the urgent need
and market opportunity for better preventive and primary care. She started
LeadinHealth to bridge the gap and ensure that user-centred, outcomes oriented,
digitally driven care could be accessible and affordable to the people.

​

Xin Yun brings deep clinical knowledge and broad experience in helping corporates and
organisations in enhancing the health and wellbeing of employees through a holistic
wellness approach. Her key specialisations are in the areas of technical consultation on
organisational wellness, as well as design and delivery of bespoke wellness and chronic
disease management programmes.

​

Her company - LeadinHealth is committed to build effective wellness culture, by creating
a new model that uses digital technology, service design, business planning and
community networks to deliver wellness and preventive care. She has recently launched
the proprietary mobile application called Walnut Wellness in delivering quality care and
health education. Her passion lies in developing and testing new models, listening and
delivering the best outcomes for clients.

​

She is holder of an Master of Business Administration, a Bachelor of Pharmacy (Hons), and a Diploma in Clinical Nutrition.

Michelle is a healthtech and insurtech consultant. She was most recently Chief Strategy Officer at the award-winning DNA-testing startup Prenetics (Hong Kong). She is a member of the Galen Growth Asia platform, an active network of healthcare and insurance ecosystem founders and stakeholders. She is also an advisor to cancer tech startup CancerAid (Sydney + Los Angeles), and consults with companies on healthtech strategies. Before making the transition into technology startups, she was a private equity and mergers and acquisitions professional.

Samson Lee is the Co-founder of Hong Kong Blockchain Centre, and the Founder and CEO of Coin Street. He is also the Founding Executive Chairman of GHM Greater Bay Area TechFin Association, and the Co-founder of Ethereum South China and South Asia communities. Samson has over 20 years of experience in TMET sector. His work is recognised with proven success across in Asia, including world’s first “charge-to-bill” mobile VAS payment service in 2000 with Hutchison n Telecom, world’s first verified-by-VISA SMS payment service with VISA and Bank of China in 2002, world’s first mobile e-wallet in 2003 with HKCSL, Asia’s first O2O e-commerce in 2004 with Li & Fung Group, Asia’s first premium Hollywood movies VOD service in 2006 with Vide online, and world’s first 4G premium VOD service in 2012 with China Mobile.

Samson holds an MBA, an MSc in Telecom & Networking from Hong Kong University of Science and Technology; and a Bachelor Degree of Commerce, from University of Toronto, Canada.

Dr. Hung-Wing Li is part of a groundbreaking team that announced in January that they have developed a compound that can provide early detection of Alzheimer's disease through small samples of saliva, urine, serum and cerebrospinal fluid. This detection method is non-invasive and cheaper, faster and more accurate than any products currently in the market. Patents have been granted and the results published in Chemical Science (DOI: 10.1039/C6SC05615F).

Dr Li obtained her BSc degree at the Chinese University of Hong Kong; her PhD degree at Iowa State University (2001-2005) followed by her post-doctorate study at University of Chicago (2005-2006). She joined Hong Kong Baptist University as Assistant Professor from 2007-2013.  Since then she is an Associate Professor at the Department of Chemistry, HKBU. Her research interest is developing sensitive detection assays for disease biomarkers employing fluorescence microscopy and nanotechnology. Recently, he work has focussed on developing direct, fast and sensitive detection assays of Alzheimer’s disease-related protein biomarkers. 

Richard is co-founder and CEO of the Vienna-based Health-AI start up ImageBiopsy Lab. He holds a PhD in mechanical engineering from the University of Technology in Vienna, focusing in his research on novel applications in medical imaging processing and artificial intelligence. Before founding ImageBiopsy Lab in 2016, Richard has spent more than 10 years working for international healthcare companies in Europe, the US and Asia. In these roles, Richard was responsible for engineering, product development and business development projects. At ImageBiopsy Lab, Richard and his team are now aiming to challenge the Status Quo of X-ray based orthopedic assessments applying a proprietary framework of artificial intelligence algorithms. 

Karin has 20 years work experience in the pharmaceutical, medical device and biotechnology industries having worked in the UK, USA, Hong Kong, China, Singapore & Sweden. She has held various senior management positions for MNC’s such as Eli Lilly, Medtronic and Baxter. She is currently the Senior Vice President of Marketing for Asia Pacific at Fresenius Medical Care. Karin’s business experiences include Strategy Development & Implementation, Sales & Marketing Management, Business & People Development, Corporate Transformations and Mergers & Acquisitions.

She has an MBA from London Business School, a Ph.D. in Genetic Engineering (King’s College, London) & recently completed the Financial Times Non Executive Director’s diploma.

In her spare time she mentors healthtech start-ups & is one of the Co-founders on the Healthcare Drinks networking event (www.healthcaredrinks.com).

Dr. Youjin Na is the CEO of Proteina, a Korean bio startup that participated in A-Stream demo day in Hong Kong earlier in 2017.

Proteina's technology is a protein-protein interaction profiling going beyond the current gene diagnostics.  What they do is to predict which targeted cancer therapy will be suitable to a certain cancer patient, and to suggest a target therapy through using the protein-protein interaction profiling technology.

They attracted a Series A funding in Korea with their pre-clinical data, and their clinical trials (on prostate, breast, lung cancer) will be finished in 1.5 years.  Now, they are looking for strategic partners or investors from all over the world, especially in Asia and US.  

Dr. Na has expertise in technology licensing and in investment. He worked as a high-tech IP expert at Samsung Electronics, and worked at the Physical Science Oncology Center under National Cancer Institute in the U.S. As a post-doctoral fellow at Northwestern University, he also devoted himself to research into DNA epigenetics.

Peter Ohnemus is the founder of the dacadoo Health Score/dacadoo ag, Zurich/Switzerland. The
patented dacadoo Health Score & Lifestyle Navigation Platform is being licensed to key Life &
Health Insurance companies (Payers) and global healthcare operators (Providers).

​

Peter has been involved in high-tech and bio-tech investments over the last 25 years and this had
led to four IPO’s and multiple trade sells.

Peter Ohnemus and his private investment firm Network Capital Holding are currently investing in
high-tech and bio-tech start-ups.

​

Peter was CEO & co-founded ASSET4 in 2004 with Goldman Sachs and Merrill Lynch as investors (the world’s leading provider of extra-financial information), which was sold to Thomson Reuters, New York in November 2009. Peter Ohnemus previously held senior executive positions with Sybase, Logic Works, The Fantastic Corporation and COS – all of which went public during his tenure. Peter Ohnemus was Entrepreneur of the Year (EoY) for Switzerland by EY.

Peter is a frequent speaker and commenter on high-tech and healthcare globally. He has spoken at World Economic Forum (WEF), Fortune Brainstorm Health, Google Tech Talks, McKinsey’s Life
Leaders CEO Forum, The Royal Society of Medicine, Stanford LIGHT Conference, CommunicAsia, Mobile World, European Health Forum by the EU, Economist Global Healthcare Forum, Mobile Health Summit DC, European Tech Tour, Red Herring, WWW/Digital Disease Detection, etc.

Over the last 10 years Peter has been board member of Rothschild Bank, Tele Denmark (Switzerland), Esbatech, CommerceOne, etc. Peter occasionally teaches digital innovation, entrepreneurship and economic impact at Universities such as HSG - Switzerland, Bocconi - India.

​

Peter lives outside Zürich, is married and has 5 daughters.

Vijay Reddy is the Founder, CEO, & CTO of PCI Technologies Corp. Nubis Health, a subdivision of PCI Technologies, is a patient health management platform that empowers patients with intelligent diagnosis and monitoring. NubisHealth provides web-based, automated eConsult for individuals who are able to utilize the vast clinical knowledgebase and check their symptoms and get potential diagnosis. This sophisticated tool is designed to analyze the profile of an individual, including the number of symptoms currently experiencing, medical/family histories, etc. The tool applies its AI to recognize the patterns to come up with diagnosis, in turn helping an individual take active role in managing their health.

​

Vijay is an entrepreneur, and a blockchain and AI enthusiast. Healthcare and Technology have a profound influence on him, and he strongly believes in innovation and cutting edge, break-through solutions. In the past 25 years, after completing his MS in Computer Science, he entered the healthcare arena with OSI Systems (Now MedAssets, Inc.) and grew to be the Chief Information officer for the company. He has also designed systems and developed software to increase efficiency and reduce costs for the healthcare entities. With his passionate drive for software development, and using his history and extensive knowledge, he hopes to continue coming up with disruptive technologies and bring innovation to the healthcare industry.

Todd Scott focuses on internal and external communications, as well as business development for Biorna Quantics. As a Biorna Professional programme writer and speaker he enjoys sharing Biorna Quantics' informed and quantitative approach to health and fitness with a wider audience.

​

Growing up in Iowa in the United States, Todd was a multi-sport student athlete and won numerous state-level accolades for wrestling and American football. At Yale University Todd earned a BA in Sociology. While there he continued club wrestling and won team and heavyweight National Championships. He was also the captain of the Yale football team in 1997.

​

Todd worked in finance in New York and Chicago, before moving to London to join Goldman Sachs in 2001. After a successful career building multiple equity index trading desks in the UK and Hong Kong he decided to pursue his passion for health and fitness.

Dr. Szyf holds a Glaxo Smith Kline and James McGill Chair in Pharmacology at McGill University in Montreal Canada and is a fellow of the Royal Society of Canada. Dr. Szyf has pioneered research in DNA methylation for the last three decades and published more than 280 papers on the biological role of DNA methylation that span a broad spectrum from basic mechanisms to cancer diagnostics and therapeutics, as well as behavior, chronic pain and addiction. He pioneered epigenetic pharmacology in cancer and as well as psychiatry epigenetics. He also founded the first Pharma in the world dedicated to DNA methylation drugs, Methylgene Inc. Last year Dr. Szyf founded Hong Kong Epitherapeutics at the Hong Kong Science Park which develops a novel class of epigenetic diagnostic markers for early detection of cancer and other diseases aimed for routine “check up” in the general population to prevent disease and increase health and well-being.

Raymond Wong, Head of Investment, Hong Kong Science and Technology Parks (HKSTP),
manages the HKSTP Corporate Venture Fund and Investment & Business Support departments.

He has over 20 years of extensive financial services experience in capital investment, portfolio
management, mergers and acquisition as well as strategic investment across different sectors in
the Asia Pacific region. Prior to HKSTP, Raymond was the Principal in HPEF Capital Partners
which is an ex-HSBC private equity firm. Prior to HSBC, Raymond worked in the capital
investment and investment banking divisions of ABN AMRO Bank. Previously, he had software
development experience at IBM Laboratory in Toronto, Canada.

Raymond obtained a Bachelor of Applied Science in Engineering Science (Computer Aided
Design and Manufacturing) from University of Toronto and a Master of Business Administration
in Finance from Columbia Business School, New York.

Seung-hee Yang is a Chief Communications Officer in Proteina. Before joining Proteina, she was an early member of a Korean software startup. As the head of business management, she managed global licensing and investment deals from negotiation to contract, especially with Chinese companies, including Wanda group. She also handled PR for multinational companies in Asia such as EA Asia and SingTel. With her diverse background and experiences, she is now looking for the next big push for Proteina globally. 

Henry Yau is the Managing Director and Honorary Assistant Professor of The University of Hong Kong Clinical Trials Centre (HKU-CTC). He holds a B.Sc. in Biochemistry and a MBA in Finance. Started his service in the pharmaceutical industry in the early-1990s, he joined HKU-CTC in 2000. Henry also undertakes roles in many local and international bodies.

​

Henry has a comprehensive range of expertise in clinical research management, including site
management organization (SMO) management, contract research organization (CRO) management and Phase 1 Centre management, and in particular in clinical research organization operation, research ethics and regulatory affairs, contract and finance management, project management, quality management, risk management and strategic business development. The  innovative study site management model he designed, namely BPAT (Business & Project Acceleration Team), is known to be an effective site management model. Over the years, he has established good collaborative relationship with close to 300 sponsors and CROs worldwide through more than 1,000 industry-sponsored clinical studies, and also facilitated some 200 investigator-initiated clinical studies.

​

Henry is dedicated to consolidating and transferring practical knowledge in clinical research
management and operations. Throughout the years, he has participated as invited speaker or panelist in over 100 conferences/forums/workshops around the world. The proprietary training program designed by him and his colleagues – PRACTISE (Professional Research Accreditation for Clinical Trials Investigative Site Executives) – was specifically designed for meeting the practical needs of clinical investigators and study site personnel worldwide. The program has gained wide recognition by medical institutions and regulatory authorities in the Asian, Middle Eastern and North African regions, and meets the criteria for recognized ICH GCP training for investigators and study site personnel mandated by TransCelerate BioPharma (an industry initiative of major international pharmaceutical companies). Henry also authored clinical research-related books and policy documents such as Clinical Research Management and Compliance at Study Sites 2010/2015), Clinical Trial Terminology Handbook (2009), Standard Operating Procedure Template for Research Ethics Committees in Hong Kong (2014), Standard Operating Procedure of the Joint Scientific Committee for Phase 1 Clinical Trials (2014), and Guideline on Ethics Oversight and Scientific Evaluation of Phase 1 Clinical Trials (2014).

Furuzonfar is an entrepreneur, investor and connector. Creating and Connecting local ecosystems to global ones where the influx of diversity, new knowledge and ultimately value can be magnified. Currently at Fresco Capital, a global venture capital firm, Furuzonfar is involved in all aspects of investment and operations. With a portfolio of 54 promising technology companies transforming education, healthcare, and the future of work, Fresco’s core mission is building global ecosystems.

​

Prior to Fresco Capital , Furuzonfar built and scaled businesses in data analytics, wealth management and investment advisory. Prior to that he was with Ernst & Young.

​

Furuzonfar graduated from the University of Hong Kong with a BA in Economics and Finance (with honours). He is a TEDx license holder, a mentor for the Laudato Si Challenge, a mentor for Founder Institute, and is an active member of the Hong Kong University and St. John’s College Alumni Club. With the Shahidi Foundation, Furuzonfar is passionate about economic and cultural empowerment.